Biosimilar injectibles via hospital direct channelAnybody know what percent (if any) of the TRX pipeline is the hospital direct channel... Yesterdays 15 Billion purchase by Phizor of Hospira, got me thinking about this..Hospira was the top company in the newly emerging Biosimilars market which will have explosive growth -- basically it is the generic versions of Biologics drugs and not the chemical compund drugs like traditiional generics...I think yesterdays deal is a hint of how biosimilar market will heat up.. These biosimilars are infusion or injection delivered as they are biological "goo"... BTW I heard Gordie Howe just flew to mexico city to be treated with a bio mix of stem cell drug and apparently he improved right away.. The drug was not fda approved so he had to go where it was available....Anyway since Biologics just started getting patented 12 years ago , products are just starting to come off patent now, but these biosimilars sell for 80% of the brand price , unlike traditional generics which are about 25%... Biosimilar market will explode over the next decade so just wondered if Tribute has any potential --- sales would be mainly to the hospital channel I think..